Can Levothyroxine Cause Elevated Liver Enzymes?

Levothyroxine can cause elevated liver enzymes, but the reaction is rare and well-documented only in scattered case reports. Far more often, the elevated enzymes that show up after starting levothyroxine trace back to the underlying thyroid disorder itself, to autoimmune conditions that travel with Hashimoto’s thyroiditis, or to dose adjustments that temporarily push thyroid hormone levels too high. Sorting out which of these is actually responsible matters, because the treatment path is different for each one.

Why Hypothyroidism Itself Raises Liver Enzymes

Before levothyroxine enters the picture, hypothyroidism on its own can disrupt liver function. The thyroid and liver are deeply intertwined: thyroid hormones regulate how the liver handles fats, proteins, and cholesterol, while the liver converts a large share of the inactive thyroid hormone T4 into the active form T3. When the thyroid underperforms, that whole loop slows down. Liver enzyme abnormalities in hypothyroid patients have been linked to impaired fat metabolism, fatty liver buildup, and a form of muscle injury caused by the hypothyroid state itself.

¹

Both hypothyroidism and hyperthyroidism can produce abnormal liver chemistries, including patterns that look like liver cell damage or bile-flow obstruction. This is especially true in more severe cases. Clinical guidelines from the American College of Gastroenterology list thyroid disease among the causes worth screening for when a patient shows up with unexplained liver enzyme elevations, recommending a TSH test as a starting point.

²

This creates a diagnostic puzzle. A person starts levothyroxine for hypothyroidism, gets blood work a few weeks later, and liver enzymes are elevated. The instinct is to blame the new medication. But in many cases, those enzymes were already climbing before the prescription started, driven by the thyroid problem itself. A study of patients with subclinical hypothyroidism found that liver markers like AST, ALT, and alkaline phosphatase were generally within normal ranges on average but showed meaningful variation, and that even mild thyroid underperformance correlated with shifts in liver chemistry.

³

When Levothyroxine Itself Is the Problem

Genuine drug-induced liver injury from levothyroxine is rare enough that the medical literature treats each confirmed case as worth publishing individually. One well-documented case involved a 63-year-old man with primary hypothyroidism who developed hepatocellular injury after roughly two months on levothyroxine. His liver enzymes climbed substantially, and the pattern pointed to drug-induced liver damage. When levothyroxine was stopped, his enzymes dropped rapidly.

⁴

Another published case followed a similar arc: a patient started levothyroxine, developed deranged liver enzymes, and recovered completely after the medication was discontinued. The researchers confirmed the diagnosis through noninvasive methods and emphasized that while rare, this adverse effect belongs in the differential when someone on levothyroxine shows liver enzyme abnormalities.

⁵

What’s reassuring about these cases is that the liver injury was self-limiting. Once the drug was removed, the liver recovered without lasting damage. But clinicians need to keep this possibility in mind precisely because it is so uncommon: the rarity means it can easily be overlooked or attributed to something else, delaying the simple fix of stopping the medication.

The Overreplacement Mechanism

One theory about why levothyroxine occasionally damages the liver focuses on the pace and size of the dose. When synthetic T4 replaces what the thyroid isn’t making, a dose that’s too high or ramped up too quickly can create a brief window of excess thyroid hormone in the body. Researchers examining a case of levothyroxine-induced liver dysfunction suspected that the relatively quick and large replacement with synthetic T4 triggered a transient thyrotoxic state, even though the patient’s thyroid function tests were technically within normal range. They proposed that genetically susceptible individuals might be especially vulnerable to this effect.

⁶

The biological reason excess thyroid hormone harms the liver comes down to oxidative stress. When thyroid hormone levels run high, cells ramp up their metabolic activity. Mitochondria work harder, and a byproduct of that extra effort is increased production of reactive oxygen species, molecules that can damage tissues. The liver, as one of the most metabolically active organs in the body, is particularly exposed. Research on hyperthyroid tissues has shown that increased mitochondrial production of these damaging molecules is essentially a side effect of the body trying to boost its metabolic capacity, and the mitochondria themselves become targets of the resulting damage.

⁷

This explains why the risk seems to cluster around dose changes rather than long-term stable use. A person who has been on the same levothyroxine dose for years with good thyroid levels is unlikely to develop liver injury from the medication. The vulnerable window is early treatment or after a dose increase, when there’s a greater chance of overshooting the target.

Excipients and Formulation Differences

Levothyroxine tablets aren’t just the active hormone. They contain inactive ingredients called excipients: fillers, binders, coatings, and dyes that vary from one manufacturer to another. When patients switch between generic brands or from brand-name to generic, changes in these excipients can cause problems, including altered drug absorption and adverse reactions. A review of levothyroxine formulations found that excipients can independently cause adverse events, separate from any effect of the thyroid hormone itself.

⁸

If your liver enzymes went up shortly after switching to a different levothyroxine brand, the excipients are worth investigating. Some people react to specific dyes or fillers, and the liver is the organ that processes these substances. This is a distinct issue from the active drug causing injury, and the fix might be as simple as switching to a different formulation rather than stopping levothyroxine altogether. Liquid and soft-gel capsule formulations have fewer excipients than traditional tablets and may be worth trying in cases where an excipient reaction is suspected.

The Autoimmune Overlap

Most people who take levothyroxine have Hashimoto’s thyroiditis, an autoimmune condition where the immune system attacks the thyroid. Autoimmune diseases tend to cluster: if you have one, you’re at higher risk for others. This matters because autoimmune hepatitis, a condition where the immune system attacks the liver, overlaps with autoimmune thyroid disease at surprisingly high rates.

A cross-sectional study found that patients with autoimmune hepatitis had autoimmune thyroid disease about 46% of the time. Patients who had overlapping autoimmune liver conditions showed even more pronounced immune markers.

⁹

Autoimmune thyroiditis and autoimmune hepatitis have been documented occurring simultaneously in the same patient, which complicates the clinical picture considerably.

¹⁰

This overlap creates a real risk of misattribution. Someone with Hashimoto’s starts levothyroxine. Liver enzymes are checked and found to be high. The medication gets blamed, but the actual culprit may be an undiagnosed autoimmune liver condition that was quietly developing alongside the thyroid problem. If liver enzymes don’t normalize after adjusting or stopping levothyroxine, autoimmune hepatitis testing should be on the list. The immune markers and antibody profiles are different enough from drug-induced injury that a gastroenterologist can usually distinguish the two.

When Levothyroxine Actually Improves Liver Enzymes

Here’s the twist that catches many people off guard: for many hypothyroid patients, starting levothyroxine makes liver enzymes better, not worse. The mechanism is straightforward. Hypothyroidism slows fat metabolism, which promotes fatty liver disease. Correcting the thyroid deficit with levothyroxine restores normal fat processing and can reverse or reduce fatty liver.

A study of patients with subclinical hypothyroidism and dyslipidemia found that those who received levothyroxine experienced decreases in both the prevalence of fatty liver disease and serum ALT levels. Patients who were not treated saw these parameters stay roughly the same.

¹¹

More recent work has confirmed this pattern. In a randomized controlled study, levothyroxine treatment significantly improved the severity of fatty liver disease in subclinical hypothyroid patients. Among those with more pronounced thyroid underfunction, fatty liver prevalence dropped to about half of what it had been before treatment. Even in milder cases, treatment brought meaningful improvement compared to no treatment.

¹²

So the net effect of levothyroxine on liver enzymes, for most patients, is positive. The medication treats the thyroid problem that was causing liver stress in the first place. The rare cases of direct drug-induced liver injury are the exception, not the rule. If anything, persistently elevated liver enzymes in someone on a stable, appropriate dose of levothyroxine should prompt investigation into other causes rather than reflexive blame on the medication.

Alkaline Phosphatase as a Special Case

Alkaline phosphatase (ALP) deserves its own mention because it comes from multiple sources in the body, not just the liver. Bone, intestine, and placenta all produce ALP. In patients on levothyroxine, particularly those on TSH-suppressive doses for thyroid cancer, elevated ALP sometimes shows up on blood work and triggers concern about liver involvement.

A study of thyroid carcinoma patients receiving levothyroxine at doses designed to suppress TSH found that about 10% had elevated alkaline phosphatase, but the elevation showed no relationship to TSH levels.

¹³

When ALP is the only liver-related marker that’s elevated, the source is often bone rather than liver. Thyroid hormone increases bone turnover, and higher doses of levothyroxine accelerate this effect. A simple additional test, called a GGT, can help sort this out. If GGT is normal and only ALP is high, the elevation is most likely coming from bone activity rather than liver damage. This distinction saves people from unnecessary liver workups and unwarranted anxiety about their medication.

Pediatric Hypothyroidism and the Liver

Children with congenital hypothyroidism, those born with an underperforming or absent thyroid, face liver-related considerations of their own. Fatty liver disease is more common in this group. One study found that fatty liver prevalence was roughly 23% in children with congenital hypothyroidism compared to about 6% in a control group, with obesity, the congenital condition itself, and average TSH levels all acting as independent risk factors.

¹⁴

For these children, levothyroxine isn’t a source of liver risk; it’s a treatment for one of the contributing causes. Adequate thyroid replacement helps normalize the metabolic environment that predisposes the liver to fat accumulation. Pediatric endocrinologists monitor liver function as part of routine care, but the goal is to optimize the levothyroxine dose, not to avoid it.

What to Do if Your Liver Enzymes Are Elevated

If you’re on levothyroxine and blood work shows elevated liver enzymes, the first step is context. Timing matters: did the elevations appear shortly after starting the drug or changing the dose? Were they present before you began treatment? How high are they? A mild bump in ALT or AST is handled very differently from a dramatic spike.

Your doctor will likely work through a checklist that includes:

• Thyroid levels: Is your current dose too high? A free T4 and TSH check can reveal whether overreplacement is producing a mildly thyrotoxic state that could stress the liver.
• Pre-existing liver conditions: Fatty liver disease, alcohol-related changes, or viral hepatitis can all elevate the same enzymes and may have been present before levothyroxine entered the picture.
• Autoimmune workup: Given the overlap between Hashimoto’s and autoimmune hepatitis, specific antibody tests can rule in or out an immune-mediated liver process.
• Other medications: Many common drugs affect liver enzymes. Statins, acetaminophen, certain antibiotics, and supplements (especially high-dose vitamin A or iron) are frequent culprits.
• Formulation change: If you recently switched brands or from brand-name to generic, an excipient reaction is possible.

If drug-induced liver injury from levothyroxine is strongly suspected, the standard approach is a supervised trial off the medication or a switch to an alternative thyroid preparation. As the published case reports show, liver enzymes typically recover quickly once the offending agent is removed. Rechallenge, restarting the same drug to confirm it was responsible, is sometimes done under close monitoring but isn’t always necessary if the clinical picture is clear.

Thyroid Cancer Patients on Suppressive Doses

People treated for thyroid cancer often take levothyroxine at deliberately higher doses than what’s used for simple hypothyroidism. The goal is to keep TSH suppressed, because TSH can stimulate growth of residual thyroid cancer cells. These suppressive doses push free T4 levels toward the upper end of the normal range or slightly above it, which means the liver is chronically exposed to more thyroid hormone than it would encounter in a person on standard replacement.

Despite this, large-scale liver injury in thyroid cancer patients on suppressive-dose levothyroxine is not a recognized pattern. The elevated ALP seen in about 10% of these patients, as noted earlier, tends to be bone-derived rather than liver-derived. Routine monitoring of liver function in this population is reasonable, but persistent abnormalities should prompt the same broad differential workup rather than automatic dose reduction, since lowering the dose could compromise cancer surveillance.

The balance here is inherently tricky. These patients need enough levothyroxine to keep TSH low, but not so much that they develop cardiovascular complications, bone loss, or, in the rare susceptible individual, liver stress. Endocrinologists typically titrate the dose carefully and track a panel of markers beyond just TSH to catch any emerging problems early.